About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
CRIPS is a research group focusing on severe acute respiratory infections and sepsis.
The objective is to develop projects on clinical and translational research in hospital-acquired pneumonia, community-acquired pneumonia, and severe viral respiratory infections, such as influenza and COVID-19. CRIPS also develop epidemiological studies focused on risk and prognostic factors for multi-resistant pathogens, validation of ventilator-associated events in ventilated adult and pediatric patients, incorporating artificial intelligence techniques. It also highlights evidence-based medicine (EBM) research, evaluating therapies and prevention strategies and participating in the formulation of clinical practice guidelines, as part of CIBERES and the European Society for Clinical Microbiology and Infections. The EBM research focuses on knowledge translation to get research findings to the point of decision making, providing health-related recommendations, focusing on clinical research and relevance of care.
CRIPS collaborate on a Local (UIC, IDIAP), National (CIBERES), and International level (CHU Nimes, Uolo University, ISARIC and Pneumo-Inspire Networks).
IP: Cristopher Alan Mazo Torre
- Promote projects involving biomarkers in management, diagnosis and monitoring of VAP, VAT, CAP, and severe sepsis
- Participation and leadership in evidence-based guidelines & Clinical trials (phase II)
IP: -
Multidisciplinary, multicenter network focusing on respiratory complications of the perioperative period and ICU re-admission
Infection control , surveillance and safety in respiratory complications focusing on respiratory infections
IP: Dimelza Osorio Sánchez Collaborators: Jesús Martínez Pérez, Karla Salas Gama, Percy Efrain Pantoja Bustillos, Anna Sala Cunill, Roser Martin Campos, Julia Salvador Lodosa, Daniel López Torres, Victoria Valls Comamala, Marta Aguayo Álvarez , Dimelza Osorio Sánchez, Cristopher Alan Mazo Torre Funding agency: Instituto de Salud Carlos III Funding: 62920 Reference: PI22/00371 Duration: 01/01/2023 - 31/12/2025
IP: Alberto Sandiumenge Camps Collaborators: César Laborda Soriano, María Deu Martín, Aroa Gomez Brey, Cristopher Alan Mazo Torre, Teresa Pont Castellana Funding agency: Instituto de Salud Carlos III Funding: 62920 Reference: PI19/01660 Duration: 01/01/2020 - 30/06/2024
IP: Antoni Soriano Arandes Collaborators: Jorgina Vila Soler, Joan Balcells Ramirez, Núria Worner Tomasa, Cristina Andrés Vergés Funding agency: Fundació La Marató de TV3 Funding: 161075 Reference: 202134 Duration: 23/09/2021 - 22/09/2024
IP: Joan Balcells Ramirez Collaborators: - Funding agency: National Institutes of Health (NIH) Funding: 9078.48 Reference: ASCEND_NIH-PA-19-056_2021 Duration: 07/07/2021 - 30/06/2025
PhD student: Sofia Tejada Magraner Director/s: Jordi Rello Condomines University: Universitat de Barcelona Year: 2023
PhD student: Cristopher Alan Mazo Torre, Cristopher Alan Mazo Torre Director/s: Jordi Rello Condomines University: Universidad Autònoma de Barcelona Year: 2020
PhD student: Sergio Andres Ramírez Estrada Director/s: Jordi Rello Condomines, Benito Almirante Gragera, Benito Almirante Gragera University: Universidad Autònoma de Barcelona Year: 2020
PhD student: Joan Balcells Ramirez, Joan Balcells Ramirez Director/s: Antonio Moreno Galdó University: Universidad Autònoma de Barcelona Year: 2019
PhD student: Bárbara Borgatta Director/s: Jordi Rello Condomines University: Universidad Autònoma de Barcelona Year: 2018
PhD student: Yolanda Peña Lopez, Yolanda Peña Lopez Director/s: Magda Campins Martí, Jordi Rello Condomines University: Universidad Autònoma de Barcelona Year: 2018
PhD student: Leonel Lagunes Luna Director/s: Magda Campins Martí, Jordi Rello Condomines University: Universidad Autònoma de Barcelona Year: 2017
PhD student: Candela Solé Lleonart , Candela Solé Lleonart Director/s: Jordi Rello Condomines University: Universidad Autònoma de Barcelona Year: 2017
PhD student: Simone Gattarello Director/s: Jordi Rello Condomines, Vicenç Falcó Ferrer University: Universidad Autònoma de Barcelona Year: 2015
PhD student: Roser Anglès Coll, Roser Anglès Coll, Roser Anglès Coll Director/s: Francisco J. de Latorre Arteche, Jaume Guardia Massó University: Universidad Autònoma de Barcelona Year: 2011
A study, in which Vall d'Hebron has participated, has analysed all the interventions of this type carried out between 2006 and 2020.
The work of the multinational team, which has reviewed the records of more than one million patients who have received a new organ, has found significant differences between women and men
The scientific review reports that changes in the respiratory system flora due to pollution increase the risk of suffering a hospital infection caused by multidrug-resistant organisms.
